NCT06226675

Brief Summary

The incidence of femoral neck fracture in Europe is 330/10000 per year. It is increasing every year due to the aging of the population. In patients 55 years and older, hip fracture-related mortality is estimated to be between 4% and 16% at one month and between 11% and 43% at one year after surgery. The reduced risk of postoperative complications associated with the use of regional anesthesia, shorter mobilization times, and reduced morphine consumption in hip fractures have been reported, and have been incorporated into postoperative pain control as part of multimodal strategies. PENG has been described for postoperative pain control for surgery on the hip joint or for the treatment of post-traumatic pain associated with proximal femur/femoral head fractures. Lateral femoral cutaneous nerve block is used in combination with other peripheral block methods to provide analgesia in the lateral thigh. The investigators aimed to evaluate the effect of adding lateral femoral cutaneous nerve block to PENG block on pain scores and opioid consumption in femoral fracture procedures under spinal anesthesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 4, 2024

Completed
22 days until next milestone

First Posted

Study publicly available on registry

January 26, 2024

Completed
5 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

January 26, 2024

Status Verified

January 1, 2024

Enrollment Period

1.1 years

First QC Date

January 4, 2024

Last Update Submit

January 17, 2024

Conditions

Keywords

lateral femoral cutaneous nerve blockPENG blockPain managementOpioid consumption

Outcome Measures

Primary Outcomes (1)

  • postoperative opioid consumption

    total morphine requirement

    up to 24 hour after surgery

Secondary Outcomes (4)

  • pain scores

    up to 24 hour after surgery

  • first analgesic time

    up to 24 hour after surgery

  • postoperative complications

    up to 24 hour after surgery

  • mobilization time

    up to 24 hour after surgery

Study Arms (3)

Group Control

NO INTERVENTION

Group PENG

ACTIVE COMPARATOR
Procedure: PENG Block

Group PENG+LFCN

ACTIVE COMPARATOR
Procedure: PENG BlockProcedure: LFCN block

Interventions

PENG BlockPROCEDURE

To apply local anesthetic under psoas tendon

Group PENGGroup PENG+LFCN
LFCN blockPROCEDURE

to apply local anesthetic around lateral femoral cutaneous nerve

Group PENG+LFCN

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old,
  • ASA I-II-III risk group
  • patients undergoing hip fracture surgery under spinal anesthesia
  • Patients whose informed consent was read and consent was obtained from them and their representatives.

You may not qualify if:

  • Those who do not want to participate in the study,
  • ASA IV-V patients
  • Those with coagulation disorders
  • Allergic to local anesthetics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zonguldak Bülent Ecevit University

Zonguldak, Kozlu, 67600, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, PostoperativeAcute PainAgnosia

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 4, 2024

First Posted

January 26, 2024

Study Start

January 1, 2023

Primary Completion

January 31, 2024

Study Completion

April 1, 2024

Last Updated

January 26, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations